Latest Marshall Edwards Inc. Stories
SAN DIEGO, June 28, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it will change its name to MEI Pharma, Inc. and its common stock will begin trading under the new ticker symbol MEIP when the market opens on Monday, July 2, 2012. (Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO) "Over the past two years we have successfully...
SAN DIEGO, June 4, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced results from a Phase I clinical trial of its lead drug candidate ME-143 in patients with solid refractory tumors. The data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago today. "We are encouraged by the results from this first-in-human study of...
SAN DIEGO, May 29, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors. The dose escalation trial is expected to enroll up to 24 patients in up to five cohorts with final...
SAN DIEGO, May 14, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the completion of its previously announced rights offering to stockholders, which expired on Friday, May 11, 2012. Results indicate that stockholders exercised subscription rights to purchase 11.7 million Units in the offering. Accordingly, the Company will issue 5.8 million shares of...
SYDNEY, May 8, 2012 /PRNewswire/ -- Novogen Limited (ASX: NRT Nasdaq: NVGN), announced today that following approval by its shareholders at an Extraordinary General Meeting held on 7 May, 2012, its Board of Directors has resolved to make a US$4 million investment in Marshall Edwards, Inc. ("MEI") under the MEI rights offering previously announced. The investment will be subject to availability of rights that have not been otherwise exercised by MEI or Novogen shareholders. On 20...
SAN DIEGO, May 8, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced that its majority shareholder, Novogen Limited, has exercised rights to acquire $4 million of Units, subject to availability, in Marshall Edwards' ongoing rights offering following approval at a meeting of Novogen stockholders in Sydney on Monday. Pursuant to the rights offering, Marshall...
SAN DIEGO, April 25, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the U.S. Patent and Trademark Office has issued Patent No. 8,163,795 covering the Company's lead drug candidate ME-143 for use in treating cancer. The patent is expected to provide protection until September 2025. The Company also announced that it has received notices of...
SAN DIEGO, April 10, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has received approval from the U.S Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for ME-344, the Company's lead mitochondrial inhibitor. The Company is now in the process of initiating a Phase I clinical trial of intravenous ME-344 in...
SAN DIEGO, April 3, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that data from a Phase I clinical trial of the Company's lead drug candidate ME-143 has been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2012, in Chicago. An abstract of the presentation, entitled "ME-143, a novel...
SAN DIEGO, March 28, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present an update on Marshall Edwards and the clinical development of its lead oncology drug candidates, ME-143 and ME-344, at the Needham Healthcare Conference on Wednesday, April 4, 2012 at 8:40 a.m. Eastern...
